Erudio Healtherudio.com
Sponsor
Novartis trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Novartis yet. Erudio has found public clinician commentary on 39 clinical trials sponsored by Novartis, including CASSIOPEIA, NATALEE, PSMAfore and SOLAR-1. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (Novartis Pharmaceuticals; Advanced Accelerator Applications; Endocyte; MorphoSys AG). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NATALEE NCT03701334 · Novartis Pharmaceuticals DeepView → | HR+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| CASSIOPEIA NCT03876769 · Novartis Pharmaceuticals DeepView → | high-risk B-cell acute lymphoblastic leukemia, EOC MRD-positive | Phase 2 | Deep | View | |||
| PSMAfore NCT04689828 · Novartis Pharmaceuticals DeepView → | taxane-naive metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| SOLAR-1 NCT02437318 · Novartis Pharmaceuticals DeepView → | HR-positive, HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| NETTER-2 NCT03972488 · Advanced Accelerator Applications DeepView → | newly diagnosed advanced grade 2-3 gastroenteropancreatic neuroendocrine tumors | Phase 3 | Deep | View | |||
| NETTER-1 NCT01578239 · Advanced Accelerator Applications DeepView → | inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors | Phase 3 | Deep | View | |||
| MANIFEST-2 NCT04603495 · Novartis Pharmaceuticals DeepView → | JAK inhibitor-naive myelofibrosis | Phase 3 | Deep | View | |||
| RIGHT Choice NCT03839823 · Novartis Pharmaceuticals DeepView → | premenopausal or perimenopausal HR-positive HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| MONALEESA-7 NCT02278120 · Novartis Pharmaceuticals DeepView → | premenopausal HR-positive HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| L-MIND NCT02399085 · MorphoSys AG DeepView → | relapsed or refractory diffuse large B-cell lymphoma | Phase 2 | Deep | View | |||
| MONALEESA-3 NCT02422615 · Novartis Pharmaceuticals DeepView → | HR-positive, HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| ELARA NCT03568461 · Novartis Pharmaceuticals DeepView → | relapsed or refractory follicular lymphoma | Phase 2 | Deep | View | |||
| BOLERO-2 NCT00863655 · Novartis Pharmaceuticals DeepView → | estrogen receptor-positive locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| ALTTO NCT00490139 · Novartis Pharmaceuticals DeepView → | HER2-positive early stage breast cancer | Phase 3 | Deep | View | |||
| ASC4FIRST NCT04971226 · Novartis Pharmaceuticals DeepView → | newly diagnosed Ph+ chronic-phase chronic myeloid leukemia | Phase 3 | Deep | View | |||
| COMBI-AD NCT01682083 · Novartis Pharmaceuticals DeepView → | high-risk BRAF V600 mutation-positive melanoma after surgical resection | Phase 3 | Deep | View | |||
| BYLieve NCT03056755 · Novartis Pharmaceuticals DeepView → | PIK3CA-mutated HR+ HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| GEOMETRY mono-1 NCT02414139 · Novartis Pharmaceuticals DeepView → | MET exon 14-mutated or MET-amplified advanced NSCLC | Phase 2 | Deep | View | |||
| PSMA-DC NCT05939414 · Novartis Pharmaceuticals DeepView → | PSMA-positive oligometastatic prostate cancer | Phase 3 | Deep | View | |||
| ELIANA NCT02435849 · Novartis Pharmaceuticals DeepView → | pediatric relapsed and refractory B-cell acute lymphoblastic leukemia | Phase 2 | Deep | View | |||
| PSMAddition NCT04720157 · Novartis Pharmaceuticals DeepView → | PSMA-positive metastatic hormone-sensitive prostate cancer | Phase 3 | Deep | View | |||
| STIMULUS-MDS1 NCT03946670 · Novartis Pharmaceuticals DeepView → | previously untreated higher-risk myelodysplastic syndromes | Phase 2 | Deep | View | |||
| CANOPY-A NCT03447769 · Novartis Pharmaceuticals DeepView → | Not given | Phase 3 | Deep | View | |||
| STIMULUS-MDS2 NCT04266301 · Novartis Pharmaceuticals StandardView → | higher risk MDS and CMML-2 | Phase 3 | Standard | View | |||
| PSMAcTION NCT06780670 · Novartis Pharmaceuticals StandardView → | PSMA-positive metastatic castration-resistant prostate cancer after [177Lu]Lu-PSMA therapy | Phase 2/Phase 3 | Standard | View | |||
| ASC2ESCALATE NCT05384587 · Novartis Pharmaceuticals StandardView → | first-line or second-line chronic-phase chronic myeloid leukemia | Phase 2 | Standard | View | |||
| KontRASt-01 NCT04699188 · Novartis Pharmaceuticals StandardView → | advanced KRAS G12C-mutated solid tumors | Phase 1/Phase 2 | Standard | View | |||
| RADIANT-2 NCT00412061 · Novartis Pharmaceuticals StandardView → | advanced neuroendocrine tumors with carcinoid syndrome | Phase 3 | Standard | View | |||
| TELESTO NCT00940602 · Novartis Pharmaceuticals FocusedView → | transfusion-dependent low- to intermediate-1-risk myelodysplastic syndromes | Phase 2 | Focused | View | |||
| ASCEND-7 NCT02336451 · Novartis Pharmaceuticals FocusedView → | ALK-positive NSCLC metastatic to brain and/or leptomeninges | Phase 2 | Focused | View | |||
| NCT02034110 NCT02034110 · Novartis Pharmaceuticals FocusedView → | Not given | Phase 2 | Focused | View | |||
| VISION NCT03511664 · Endocyte FocusedView → | PSMA-positive metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| CDFF332A12101 NCT04895748 · Novartis Pharmaceuticals FocusedView → | advanced/relapsed ccRCC and malignancies with HIF2α stabilizing mutations | Phase 1 | Focused | View | |||
| JULIET NCT02445248 · Novartis Pharmaceuticals FocusedView → | adult relapsed/refractory diffuse large B-cell lymphoma | Phase 2 | Focused | View | |||
| NCT03114319 NCT03114319 · Novartis Pharmaceuticals FocusedView → | advanced solid tumors | Phase 1 | Focused | View | |||
| GEOMETRY-N NCT04926831 · Novartis Pharmaceuticals FocusedView → | Not given | Phase 2 | Focused | View | |||
| BELINDA NCT03570892 · Novartis Pharmaceuticals FocusedView → | Not given | Phase 3 | Focused | View | |||
| AMALEE NCT03822468 · Novartis Pharmaceuticals FocusedView → | first-line HR-positive HER2-negative advanced breast cancer | Phase 2 | Focused | View | |||
| NCT05142696 NCT05142696 · Novartis Pharmaceuticals FocusedView → | newly diagnosed extensive-stage small cell lung cancer | Phase 1/Phase 2 | Focused | View | |||